179 related articles for article (PubMed ID: 10861649)
1. Hepatitis B e antigen seroconversion: effects of lamivudine alone or in combination with interferon alpha.
Farrell G
J Med Virol; 2000 Jul; 61(3):374-9. PubMed ID: 10861649
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
[TBL] [Abstract][Full Text] [Related]
4. Short-term lamivudine therapy in patients with chronic hepatitis B.
Chien RN; Liaw YF
Intervirology; 2003; 46(6):362-6. PubMed ID: 14688453
[TBL] [Abstract][Full Text] [Related]
5. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
6. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.
van Nunen AB; Hansen BE; Suh DJ; Löhr HF; Chemello L; Fontaine H; Heathcote J; Song BC; Janssen HL; de Man RA; Schalm SW
Gut; 2003 Mar; 52(3):420-4. PubMed ID: 12584227
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients.
Guptan RC; Thakur V; Kazim SN; Sarin SK
J Gastroenterol Hepatol; 2002 Jul; 17(7):765-71. PubMed ID: 12121506
[TBL] [Abstract][Full Text] [Related]
8. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study.
Zhu S; Zhang H; Dong Y; Wang L; Xu Z; Liu W; Gan Y; Tang H; Chen D; Wang F; Zhao P
J Hepatol; 2018 Jun; 68(6):1123-1128. PubMed ID: 29452204
[TBL] [Abstract][Full Text] [Related]
9. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
[TBL] [Abstract][Full Text] [Related]
10. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
Yue W; Yuan H; Mao XR; Deng YD; Chen L
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
[TBL] [Abstract][Full Text] [Related]
11. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.
Schalm SW; Heathcote J; Cianciara J; Farrell G; Sherman M; Willems B; Dhillon A; Moorat A; Barber J; Gray DF
Gut; 2000 Apr; 46(4):562-8. PubMed ID: 10716688
[TBL] [Abstract][Full Text] [Related]
12. [Preliminary results of interferon alpha-2a and lamivudine combination therapy regimen in children with chronic hepatitis B].
Aşik Akman S; Cokçeken Okçu S; Anil OH; Köse S; Bakiler AR
Mikrobiyol Bul; 2006; 40(1-2):47-53. PubMed ID: 16775956
[TBL] [Abstract][Full Text] [Related]
13. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.
Perrillo RP; Lai CL; Liaw YF; Dienstag JL; Schiff ER; Schalm SW; Heathcote EJ; Brown NA; Atkins M; Woessner M; Gardner SD
Hepatology; 2002 Jul; 36(1):186-94. PubMed ID: 12085364
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial.
Karabay O; Tamer A; Tahtaci M; Vardi S; Celebi H
J Microbiol Immunol Infect; 2005 Aug; 38(4):262-6. PubMed ID: 16118673
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine.
Flink HJ; Hansen BE; Heathcote EJ; Feinman SV; Simsek H; Karayalcin S; Mach T; Leemans WF; de Man RA; Verhey E; Schalm SW; Janssen HL;
Am J Gastroenterol; 2006 Nov; 101(11):2523-9. PubMed ID: 17029610
[TBL] [Abstract][Full Text] [Related]
16. Management of hepatitis B in China.
Yao GB
J Med Virol; 2000 Jul; 61(3):392-7. PubMed ID: 10861652
[TBL] [Abstract][Full Text] [Related]
17. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
[TBL] [Abstract][Full Text] [Related]
18. Lamivudine therapy for children with chronic hepatitis B.
Liberek A; Szaflarska-Popławska A; Korzon M; Łuczak G; Góra-Gebka M; Łoś-Rycharska E; Bako W; Czerwionka-Szaflarska M
World J Gastroenterol; 2006 Apr; 12(15):2412-6. PubMed ID: 16688835
[TBL] [Abstract][Full Text] [Related]
19. Management of viral hepatitis B.
Pramoolsinsup C
J Gastroenterol Hepatol; 2002 Feb; 17 Suppl():S125-45. PubMed ID: 12000599
[TBL] [Abstract][Full Text] [Related]
20. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]